A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
← catalyst calendarNCT07597018 · readout in 282 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
234estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-18 | actual | When the study began enrolling |
| Primary completion | 2027-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Cagrilintide D
- Drug: Cagrilintide B and placebo semaglutide I
Primary outcomes
what the primary-completion date above is the date OFAUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c.
measured Day 113 (pre-dose) to Day 120 (post-dose)
Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c.
measured Day 113 (pre-dose) to Day 120 (post-dose)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed